Montana ...IMHO it becomes a race to the bottom . Profits margins will be very tight or non existent unless AMRN dramatically cuts marketing expense. . If they cut marketing expense ...how do they build market .
The Epipen market was well established ....so cutting the price provided Mylan with a lot of free positive marketing . Priced low enough no need to switch .....and no more / very little marketing costs needed for their Epipen
If Vascepa was well established in the US and EU then the strategy might work ...but unfortunately that's not the case
The drug and device combo we now know as an EpiPen was first approved by the FDA in 1987.
News 
Market Data 
Discover 
